HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $7 Price Target
PDS Biotechnology Corp.
PDS Biotechnology Corp. PDSB | 0.00 |
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:
PDSB) with a Buy and maintains $7 price target.
